We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Winner of Qualcomm Tricorder XPrize Unveiled at AACC

By LabMedica International staff writers
Posted on 08 Jun 2017
A highlight of the July 30 - August 3, 2017, AACC Annual Scientific Meeting & Clinical Lab Expo (San Diego, CA, USA) will be the session dedicated to the unveiling of the winner of the Qualcomm Tricorder XPrize (Culver City, CA, USA) competition.

The 10 million USD global competition, which was announced in 2012, challenged 34 research teams to produce a lightweight device (a "tricorder") that consumers could have at their fingertips to diagnose a health condition or monitor their vital signs without the need to consult a medical professional. More...
To qualify the device had to be capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms).

In the science-fictional Star Trek universe, a tricorder was a multifunction hand-held device used for sensor scanning, data analysis, and recording data. The standard tricorder was a general-purpose device used primarily to scout unfamiliar areas, make detailed examination of living things, and record and review technical data. The medical tricorder was used by doctors to help diagnose diseases and collect bodily information about a patient; the key difference between this and a standard tricorder was a detachable hand-held high-resolution scanner stored in a compartment of the tricorder when not in use.

The winner of the top prize of 2.6 million USD was Final Frontier Medical Devices, a Pennsylvania-based team led by Dr. Basil Harris, an emergency medicine physician, and his brother George Harris, a network engineer, for their artificial intelligence-based engine, DxtER, which learns to diagnose medical conditions by integrating learnings from clinical emergency medicine with data analysis from actual patients.

DxtER was designed to monitor the individual's health and diagnose illnesses away from the hospital or doctor's office setting. DxtER functions autonomously, but can also share important information with healthcare providers. At the heart of DxtER is an artificially intelligent engine that learned to diagnose by integrating years of experience in clinical emergency medicine with data analysis from actual patients having a variety of medical conditions and outcomes. Included with DxtER is an assortment of non-invasive sensors custom-designed to collect data about vital signs, body chemistry, and biological functions. The diagnostic engine synthesizes the health data to make a quick and accurate assessment.

Dynamical Biomarkers Group was awarded the second place in the Qualcomm Tricorder XPRIZE competition for their prototype, which links diagnostic algorithms with analytical methodology in a user-friendly device, all controlled through a smartphone.

Final Frontier Medical Devices team member Philip Charron and Dynamical Biomarkers Group team member Dr. Chung-Kang Peng will describe their revolutionary technologies in a major session at the 69th AACC Annual Scientific Meeting.

Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
Qualcomm Tricorder XPrize


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.